News
AMRX
20.14
+3.55%
0.69
CoreWeave And 2 Other Top Growth Stocks With Insider Buying
Simply Wall St · 2d ago
Amneal Pharmaceuticals price target raised to $28 from $25 at UBS
TipRanks · 2d ago
Amneal Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Dow Jones · 3d ago
Amneal Pharmaceuticals Price Target Raised to $25.00/Share From $23.00 by Leerink Partners
Dow Jones · 3d ago
Leerink Partners Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)
TipRanks · 3d ago
Amneal Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 4d ago
Amneal Pharmaceuticals Price Target Raised to $25.00/Share From $24.00 by JP Morgan
Dow Jones · 4d ago
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25
Benzinga · 4d ago
Will Raised 2026 Guidance Change Amneal Stock Narrative
Simply Wall St · 4d ago
Amneal (AMRX) Q3 2026 Earnings Call Transcript
The Motley Fool · 5d ago
Amneal Pharmaceuticals, Inc. Reports Third Quarter 2026 Net Revenue of $863 million
NASDAQ · 5d ago
Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga · 5d ago
Amneal Pharmaceuticals Reports Strong Third-Quarter 2026 Financial Results
TipRanks · 5d ago
Amneal Pharmaceuticals (AMRX) Receives a Buy from Oppenheimer
TipRanks · 5d ago
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
NASDAQ · 5d ago
Amneal Pharma Posts Wider Q3 Loss Despite 10% Revenue Growth; Raises FY26 Outlook
NASDAQ · 5d ago
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
NASDAQ · 5d ago
Amneal raises 2026 forecast but lowers operating cash flow outlook
Seeking Alpha · 5d ago
Amneal Pharmaceuticals raises FY26 adjusted EPS to $1.04-$1.08 from 96c-$1.06
TipRanks · 5d ago
*Amneal Pharmaceuticals Raises FY26 View To Adj EPS $1.04-Adj EPS $1.08 >AMRX
Dow Jones · 5d ago
More
Webull provides a variety of real-time AMRX stock news. You can receive the latest news about Amneal Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.